November 23, 2013
by Matthew Pomy
The Supreme Court of Canada on Friday upheld a ban on pharmacies selling their own generic drug brands. The ruling addresses the Drug Interchangeability and Dispensing Fee Act and the Ontario Drug Benefit Act which were meant to control the rising price of pharmaceuticals. Under this scheme, ...[read more]
April 11, 2013
by Endia Vereen
JURIST Guest Columnist, Daniel Perrone, St. John's University School of Law Class of 2013, discusses the implications of the US Supreme Court decision insulating generic drug manufacturers from liability against failure to warn claims...In 2011, generic drugs accounted for nearly 80 percent of the ...[read more]
March 20, 2013
by Julia Zebley
The US Supreme Court heard arguments in Mutual Pharmaceutical Company, Inc. v. Bartlett Tuesday to consider whether design defect claims can be brought when a generic drug does not present all the warnings the brand-name version of the drug does, and thus causes injury. Attorneys for Mutual ...[read more]
June 23, 2011
by Julia Zebley
The US Supreme Court on Thursday voted 5-4 to reverse the lower court in PLIVA, Inc. v. Mensing, holding that since generic drugs and their warnings are managed by the Food and Drug Administration (FDA), their federal regulations on warning labels preempt state law on warning labels. Justice ...[read more]
May 22, 2008
by Andrew Gilmore
Drug companies are harming consumers by using pay-for-delay legal agreements to keep cheaper generic prescription drugs off the market, according to a report released Wednesday by the US Federal Trade Commission (FTC). The report compares legal documents submitted to the FTC by drug man... ...[read more]

Support JURIST

We rely on our readers to keep JURIST running

 Donate now!

© Copyright JURIST Legal News and Research Services, Inc., 2013.